Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. - Wikidata - awgldk - TriplyDB

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

http://www.wikidata.org/entity/Q37244349

about

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Strategies for combining immunotherapy with radiation for anticancer therapy Adoptive T-cell therapy for cancer: The era of engineered T cells Adoptive T-cell therapy for Leukemia Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells Recent advances in T-cell engineering for use in immunotherapy Smart CARs engineered for cancer immunotherapy Designing chimeric antigen receptors to effectively and safely target tumors Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells CAR-modified T-cell therapy for cancer: an updated review.Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Versatile strategy for controlling the specificity and activity of engineered T cells.Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy.Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.Nature Biotechnology's academic spinouts of 2013.DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

P2860

Q26778759-4989683B-2CA4-4206-BDB0-25074071C4D8 Q26795540-5A0EF1E5-8CF7-4279-ADAF-C94B3CFA3C25 Q26796675-42359D3B-85F8-47FB-BA91-92ECC3383C37 Q26800611-659E091A-17DC-4BA8-9CD9-9E7F500B2F51 Q27006934-DD06876A-9BC9-4F51-B021-31DE35DDFEBE Q27022477-6006A198-EC89-4C86-B6D3-F365490E20E6 Q27025300-4D8B3B43-973A-407E-89E3-7D56FA1BDF2F Q27026484-A2FAEB1B-F8AF-4E71-B506-DA1148A110ED Q28080312-4B32673A-FC3E-4322-A7BC-0075D48D851C Q28087236-011065AC-9C0D-450C-8219-96EF3698208B Q28088526-491C60B7-14F1-461F-B660-EB25BB65D380 Q28276800-96163244-72D3-4F70-ADCD-1C36BD1EFCFF Q28547292-B16F2EFA-5F3D-4FC6-93FB-E9426AD0CFA1 Q28551080-33078E92-69EE-44EA-8326-95287D7E2F8B Q28553650-6B8043E5-1DAE-431E-A785-3FB9A798AC8F Q30764873-70C7BD96-885B-4406-8D0F-31C93F47F484 Q33692070-9459C5AB-1A41-4DEE-87C8-92477C1F9941 Q33779292-9BCB6D7B-1E6E-4595-8335-77F0075184C5 Q33833475-BE43A374-7042-46CE-AA52-AB37C560ED32 Q34044213-3CC7CD96-F867-4E73-B307-0DEF5B352680 Q34044910-3D09F30E-A87B-4866-B958-73445617EA28 Q34045831-91EBA880-2273-44C1-973D-99D23F75245A Q34046252-3F1A7FE9-D34E-4B55-85A7-6D6A1FF2B218 Q34069803-B4468C1D-A283-42CE-8C87-B05C42026BC1 Q34256494-6689B114-E2BA-4467-8D6A-8D83723EF727 Q34309388-7F683FC7-DDA7-4FD0-818F-350F812CF78B Q34434111-7FD58763-DF7E-4E02-9078-EAD8801F728F Q34747359-EF49E815-5B32-4FC6-A02E-05FF1B6CAECC Q35071430-467EFC18-37F6-4573-AA7C-F8FE3198D8E7 Q35146529-A179ACD9-8B30-4F87-9CA8-489A0825C870 Q35209066-147C4A87-70A2-4516-92B3-49DF83DEB8B3 Q35399080-1500F212-B485-420D-AB32-9141ACC21F81 Q35648352-7AEA8BD9-55A6-4D80-AB03-4C9C904AB0E4 Q35661999-771DAD59-3845-4172-BC67-AF8A2899C8B8 Q35690979-6367C405-689C-48DE-9A5B-811FE82180EE Q35980893-534886A8-EF41-42AF-B66A-B4AA5E320ECA Q36028047-5E522167-D95A-46A2-9689-537273D4CC56 Q36218880-F4331C75-EAF4-4FFC-90FA-4D070CD180B7 Q36281920-4BEEB193-6482-4E0F-901A-1BED8DF627F5 Q36408432-A3C79AD3-8FD5-43C0-8893-F39628CBD765

P2860

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

http://www.wikidata.org/entity/Q37244349

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Receptor affinity and extracel ...... eric antigen receptor T cells.

@en

Receptor affinity and extracel ...... eric antigen receptor T cells.

@nl

type

label

Receptor affinity and extracel ...... eric antigen receptor T cells.

@en

Receptor affinity and extracel ...... eric antigen receptor T cells.

@nl

prefLabel

Receptor affinity and extracel ...... eric antigen receptor T cells.

@en

Receptor affinity and extracel ...... eric antigen receptor T cells.

@nl

P1433

Q37244349-5FC5B81E-F4A5-4595-B5F7-E4569BB15E75

P1476

Q37244349-83809649-7BDF-4D42-9941-3AD5C0DA7657

P2093

Q37244349-03407C23-B31C-4A5D-A54E-0EF9372A0E86

Q37244349-03E59605-38E3-4AC1-A0D1-F81165FA3813

Q37244349-0BE51A84-675C-4CF2-A738-057BD1E7B474

Q37244349-12B467CB-217F-4DEB-B131-3E05A3375F8A

Q37244349-3010824D-4918-4C73-9CBC-8F9E95962CE5

Q37244349-4FA07391-9FC2-4522-B22A-51756FB91D9A

Q37244349-E741B9D9-5D11-43EA-8B96-9CFF3E22A824

P2860

Q37244349-0372CF49-79AF-46F8-95A1-337A3B8D89CF

Q37244349-0872E510-C905-49D2-B95F-199F9FCF5F5D

Q37244349-1352A13A-F697-41F9-B886-74CD81F72775

Q37244349-177754DD-D9C2-4B43-94B4-7833F4A52B9D

Q37244349-17EB36B0-D41C-4AB7-8461-97DB43174BA8

Q37244349-365E5DB2-8BBF-41E6-8988-C4E96484668C

Q37244349-3781D777-CC9B-4363-941F-13A58FB58369

Q37244349-3DE1D580-D18F-419B-962A-C9D9B4F077F0

Q37244349-40B8D5C0-A027-4E21-859A-55B34343099A

Q37244349-41FFD4F2-B469-4718-9E0C-3A08FAB904B0

P304

Q37244349-D2292078-A4DC-420D-8454-5311EEA7B351

P31

Q37244349-E74429CB-BA32-420A-8E99-E14C90CBFE35

P356

Q37244349-D5ACB8D8-509B-4BB5-857C-29E8531E5C9D

P407

Q37244349-85C88E49-35CA-4E8C-9A2D-2C446F063F26

P433

Q37244349-046E0776-F546-44F1-B7AF-0E93DB920CD3

P478

Q37244349-33A933F8-08EC-4B2D-8AAB-8DBBF23ED776

P577

Q37244349-5398275B-D949-4361-891F-12DFA227E2C2

P698

Q37244349-1C572CB3-57CB-4519-B3FA-798286C5998C

P932

Q37244349-70AA5D79-F67C-4389-B5DC-F350DBCC1848

P356

1078-0432.CCR-13-0330

P1433

Clinical Cancer Research

P1476

Receptor affinity and extracel ...... eric antigen receptor T cells.

@en

P2093

Christoph Rader

http://www.w3.org/2001/XMLSchema#string

Daniel Sommermeyer

http://www.w3.org/2001/XMLSchema#string

Maria-Teresa Lupo-Stanghellini

http://www.w3.org/2001/XMLSchema#string

Michael C Jensen

http://www.w3.org/2001/XMLSchema#string

Michael Hudecek

http://www.w3.org/2001/XMLSchema#string

Paula L Kosasih

http://www.w3.org/2001/XMLSchema#string

Stanley R Riddell

http://www.w3.org/2001/XMLSchema#string

P2860

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Cancer regression in patients after transfer of genetically engineered lymphocytes

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

P304

3153-3164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0330

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23620405

http://www.w3.org/2001/XMLSchema#string

P932

3804130

http://www.w3.org/2001/XMLSchema#string